Enterprise Therapeutics’ ETD001 Receives Rare Pediatric Disease Designation from FDA for Cystic Fibrosis Treatment

Enterprise Therapeutics’ ETD001 Receives Rare Pediatric Disease Designation from FDA for Cystic Fibrosis Treatment The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease (RPD) designation to ETD001, an investigational therapy developed by Enterprise Therapeutics aimed at treating cystic fibrosis (CF). This significant milestone marks a pivotal step in the development of treatments […]